This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Provention Bio Future Growth
Future criteria checks 5/6
Key information
75.7%
Earnings growth rate
64.7%
EPS growth rate
| Pharmaceuticals earnings growth | 21.9% |
| Revenue growth rate | 42.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 31 Mar 2023 |
Recent future growth updates
Recent updates
Provention Bio appoints O'Brien as Chief People Officer
Sep 19Provention Bio secures $125M term loan facility
Sep 01Provention Bio: More Risk, More Dilution Ahead - Downgrading To A Sell Rating
Aug 12Provention Bio Q2 2022 Earnings Preview
Aug 03Provention Bio to raise $60M through private placement of securities
Jul 08Provention Bio says FDA extends review period for co's teplizumab application to Nov. 17
Jun 30Provention Bio (PRVB): BLA Accepted; Downgrading To A Hold
Mar 31Provention Bio: Upgrading To A Strong-Buy, Potential Cure For Type 1 Diabetes
Feb 04Is Provention Bio (NASDAQ:PRVB) In A Good Position To Invest In Growth?
Jan 11
Is Provention Bio (NASDAQ:PRVB) In A Good Position To Deliver On Growth Plans?
Aug 26Provention Bio: Blood (Glucose) In The Streets
Jul 30FDA Advisory Committee supports Provention Bio's teplizumab in delaying diabetes
May 28Provention Bio EPS misses by $0.05
May 06Provention Bio provides regulatory update on teplizumab BLA
Apr 27How Much Of Provention Bio, Inc. (NASDAQ:PRVB) Do Insiders Own?
Mar 17Need To Know: Provention Bio, Inc. (NASDAQ:PRVB) Insiders Have Been Buying Shares
Feb 10
Provention Bio prices $100M stock offering
Jan 14Provention Bio Could See Meaningful Upside Once Teplizumab Hits The Market
Jan 07Provention Bio (NASDAQ:PRVB) Is In A Good Position To Deliver On Growth Plans
Jan 06Provention Bio files US application for its diabetes drug
Jan 04Provention Bio launches first-in-human PRV-101 study in coxsackievirus B
Dec 15Is Provention Bio, Inc.'s (NASDAQ:PRVB) Shareholder Ownership Skewed Towards Insiders?
Dec 02Provention Bio EPS misses by $0.14
Nov 05Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 452 | 168 | 34 | 179 | 3 |
| 12/31/2024 | 180 | -13 | -134 | -78 | 4 |
| 12/31/2023 | 47 | -159 | -201 | -139 | 2 |
| 12/31/2022 | 13 | -114 | -76 | -75 | N/A |
| 9/30/2022 | 3 | -106 | -91 | -91 | N/A |
| 6/30/2022 | 3 | -105 | -93 | -92 | N/A |
| 3/31/2022 | 2 | -104 | -95 | -94 | N/A |
| 12/31/2021 | 1 | -114 | -96 | -95 | N/A |
| 9/30/2021 | 1 | -121 | -98 | -97 | N/A |
| 6/30/2021 | N/A | -125 | -98 | -96 | N/A |
| 3/31/2021 | N/A | -118 | -85 | -84 | N/A |
| 12/31/2020 | N/A | -99 | -77 | -76 | N/A |
| 9/30/2020 | N/A | -77 | -62 | -61 | N/A |
| 6/30/2020 | N/A | -55 | -46 | -46 | N/A |
| 3/31/2020 | N/A | -45 | -38 | -38 | N/A |
| 12/31/2019 | N/A | -43 | -36 | -36 | N/A |
| 9/30/2019 | N/A | -38 | -32 | -32 | N/A |
| 6/30/2019 | N/A | -34 | -29 | -29 | N/A |
| 3/31/2019 | N/A | -33 | -24 | -24 | N/A |
| 12/31/2018 | N/A | -27 | -23 | -23 | N/A |
| 9/30/2018 | N/A | -25 | -20 | -20 | N/A |
| 6/30/2018 | N/A | -21 | -15 | -15 | N/A |
| 3/31/2018 | N/A | -15 | -11 | -11 | N/A |
| 12/31/2017 | N/A | -9 | -5 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRVB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).
Earnings vs Market: PRVB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PRVB is expected to become profitable in the next 3 years.
Revenue vs Market: PRVB's revenue (42.8% per year) is forecast to grow faster than the US market (7% per year).
High Growth Revenue: PRVB's revenue (42.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PRVB's Return on Equity is forecast to be high in 3 years time